Research Analysts Set Expectations for SYRS Q1 Earnings

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) – Equities researchers at HC Wainwright issued their Q1 2025 EPS estimates for shares of Syros Pharmaceuticals in a research note issued on Wednesday, November 13th. HC Wainwright analyst A. Fein forecasts that the company will post earnings of ($0.70) per share for the quarter. HC Wainwright has a “Neutral” rating and a $1.00 price objective on the stock. The consensus estimate for Syros Pharmaceuticals’ current full-year earnings is ($2.99) per share. HC Wainwright also issued estimates for Syros Pharmaceuticals’ Q2 2025 earnings at ($0.72) EPS, Q3 2025 earnings at ($0.68) EPS and Q4 2025 earnings at ($0.69) EPS.

Syros Pharmaceuticals (NASDAQ:SYRS) last posted its quarterly earnings results on Thursday, October 31st. The company reported ($0.68) EPS for the quarter, topping the consensus estimate of ($0.76) by $0.08. During the same quarter last year, the firm posted ($1.35) EPS.

SYRS has been the subject of several other research reports. TD Cowen restated a “hold” rating on shares of Syros Pharmaceuticals in a report on Wednesday. StockNews.com cut shares of Syros Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, November 4th. Piper Sandler restated an “overweight” rating and issued a $5.00 target price (down previously from $13.00) on shares of Syros Pharmaceuticals in a report on Tuesday, August 13th. JMP Securities restated a “market perform” rating on shares of Syros Pharmaceuticals in a report on Wednesday. Finally, Brookline Capital Management reiterated a “hold” rating on shares of Syros Pharmaceuticals in a research report on Wednesday. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and one has issued a buy rating to the stock. Based on data from MarketBeat, Syros Pharmaceuticals currently has an average rating of “Hold” and a consensus target price of $3.33.

Syros Pharmaceuticals Trading Down 23.4 %

Shares of Syros Pharmaceuticals stock opened at $0.28 on Friday. The company has a fifty day simple moving average of $2.04 and a 200-day simple moving average of $3.81. Syros Pharmaceuticals has a 12-month low of $0.27 and a 12-month high of $8.17. The company has a debt-to-equity ratio of 1.97, a quick ratio of 2.25 and a current ratio of 2.25.

Hedge Funds Weigh In On Syros Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in SYRS. Opaleye Management Inc. grew its stake in shares of Syros Pharmaceuticals by 119.1% during the 1st quarter. Opaleye Management Inc. now owns 787,545 shares of the company’s stock worth $4,213,000 after purchasing an additional 428,175 shares during the period. Kennedy Capital Management LLC acquired a new stake in Syros Pharmaceuticals in the 1st quarter valued at about $2,166,000. Vanguard Group Inc. grew its stake in Syros Pharmaceuticals by 21.3% in the 1st quarter. Vanguard Group Inc. now owns 928,046 shares of the company’s stock valued at $4,965,000 after acquiring an additional 163,234 shares during the last quarter. Certuity LLC acquired a new stake in Syros Pharmaceuticals in the 2nd quarter valued at about $109,000. Finally, Acadian Asset Management LLC grew its stake in Syros Pharmaceuticals by 101.5% in the 2nd quarter. Acadian Asset Management LLC now owns 34,578 shares of the company’s stock valued at $178,000 after acquiring an additional 17,416 shares during the last quarter. 91.47% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, CFO Jason Haas purchased 45,344 shares of the stock in a transaction dated Thursday, September 12th. The shares were acquired at an average cost of $1.68 per share, with a total value of $76,177.92. Following the purchase, the chief financial officer now directly owns 124,552 shares in the company, valued at $209,247.36. This trade represents a 57.25 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Conley Chee purchased 50,000 shares of the stock in a transaction dated Tuesday, September 10th. The shares were bought at an average cost of $1.51 per share, for a total transaction of $75,500.00. Following the completion of the purchase, the chief executive officer now owns 72,504 shares in the company, valued at approximately $109,481.04. This trade represents a 222.18 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last quarter, insiders bought 130,707 shares of company stock worth $206,491. 12.26% of the stock is owned by insiders.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.